CA3309723A1 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function - Google Patents
Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive functionInfo
- Publication number
- CA3309723A1 CA3309723A1 CA3309723A CA3309723A CA3309723A1 CA 3309723 A1 CA3309723 A1 CA 3309723A1 CA 3309723 A CA3309723 A CA 3309723A CA 3309723 A CA3309723 A CA 3309723A CA 3309723 A1 CA3309723 A1 CA 3309723A1
- Authority
- CA
- Canada
- Prior art keywords
- pat
- leucine
- acetyl
- claimtext
- claimnumber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606834 | 2016-04-19 | ||
| GB1606834.8 | 2016-04-19 | ||
| CA3021155A CA3021155A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3021155A Division CA3021155A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3309723A1 true CA3309723A1 (en) | 2026-06-21 |
Family
ID=58633040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3309723A Pending CA3309723A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| CA3021155A Pending CA3021155A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3021155A Pending CA3021155A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (enExample) |
| EP (2) | EP3445351B1 (enExample) |
| JP (3) | JP7387264B2 (enExample) |
| KR (4) | KR102632670B1 (enExample) |
| CN (2) | CN109069463B (enExample) |
| AU (2) | AU2017252507B2 (enExample) |
| BR (1) | BR112018071547A2 (enExample) |
| CA (2) | CA3309723A1 (enExample) |
| DK (1) | DK3445351T3 (enExample) |
| ES (1) | ES2994242T3 (enExample) |
| FI (1) | FI3445351T3 (enExample) |
| HR (1) | HRP20241552T1 (enExample) |
| HU (1) | HUE069219T2 (enExample) |
| IL (3) | IL293266B2 (enExample) |
| LT (1) | LT3445351T (enExample) |
| MD (1) | MD3445351T2 (enExample) |
| MX (2) | MX388461B (enExample) |
| PL (1) | PL3445351T3 (enExample) |
| PT (1) | PT3445351T (enExample) |
| RS (1) | RS66142B1 (enExample) |
| RU (1) | RU2745912C2 (enExample) |
| SG (2) | SG10202106190RA (enExample) |
| SI (1) | SI3445351T1 (enExample) |
| SM (1) | SMT202400459T1 (enExample) |
| WO (1) | WO2017182802A1 (enExample) |
| ZA (1) | ZA201806849B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3445351T (pt) | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| TN2019000033A1 (fr) | 2016-08-11 | 2020-07-15 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| CN120157593A (zh) | 2018-12-06 | 2025-06-17 | 内在生物技术有限公司 | 乙酰基-亮氨酸的氘代类似物 |
| CN119097618A (zh) * | 2019-03-02 | 2024-12-10 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| MD3989962T2 (ro) * | 2019-06-28 | 2025-12-31 | Intrabio Ltd Gb | Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| WO2025019570A1 (en) | 2023-07-18 | 2025-01-23 | Sytheon Ltd. | Novel amino acid based salts, compositions and methods for treating skin and rejuvenating skin and extending longevity |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| AU2007352854A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| WO2011025518A1 (en) * | 2009-08-27 | 2011-03-03 | Albert Einstein College Of Medicine Of Yeshiva University | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| PT3445351T (pt) * | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| EP3697406A1 (en) * | 2017-10-18 | 2020-08-26 | IntraBio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 CA CA3309723A patent/CA3309723A1/en active Pending
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Also Published As
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL Effective date: 20260427 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260427 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260427 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20260512 |
|
| A18 | Application divided or continuation or continuation in part accepted |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260512 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260512 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260512 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260512 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260521 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20260521 |
|
| Q12 | Application published |
Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION) Effective date: 20260621 |